Nabi Biopharmaceuticals saw biopharmaceutical product sales -
driven by strong growth in sales of Nabi-HB - reaching record
levels of $89.5 million (€83m) in 2002, a 22 per cent increase from
US demand for combinatorial chemistry products and services is set
to increase by more than twelve per cent annually to reach $4
billion (€3.7bn) in 2006, according to a new report from market
analyst the Freedonia group.
US TransTech Pharma has completed two rounds of investments in the
company, extending over the last nine months, totalling $24.5
million (€22.8m). The investments came from its largest
shareholder, New York-based MacAndrews &...
Exten Industries reported today that its wholly owned subsidiary,
MultiCell Technologies, a liver cell engineering and research
organisation in Warwick, US has just signed a nonexclusive license
agreement with a major pharmaceutical...
In relation to recent media comments relating to its
commercialisation discussions UK company GW Pharmaceuticals said in
a statement this week that it has consistently stated its
commercial strategy 'to be to enter into partnerships...
As in-licensing opportunities are reduced and competition for
market share in Japan increases with the rising penetration of
western pharma companies, domestic mid-cap players must alter their
strategies to remain independent, writes...
US company Molecular Devices, a supplier of bioanalytical
measurement systems, announced its revenues and earnings for the
quarter and year ended 31 December, 2002. Revenues for the fourth
quarter of 2002 were a healthy $30.2 million,...
German chemicals company Degussa has sold its Frankfurt/Main-based
biopharmaceutical company Zentaris to Canadian firm AEterna
Laboratories for approximately €50 million, the company said last
week. The move marks the much-talked...